AstraZeneca and Daiichi Sankyo are preparing regulatory filings that could make their HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the first ...
Choosing one over the other depends on why you need the funds Christina Majaski writes and edits finance, credit cards, and travel content. She has 14+ years of experience with print and digital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback